Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus: A comparison of two preoperative radiochemotherapy regimens;Cisplatin- vs. oxaliplatinbasierte Radiosensitizer-Chemotherapie beim Ösophagusplattenepithelkarzinom: Ein Vergleich zweier präoperativer Radiochemotherapieregime

Strahlentherapie und Onkologie

Volumn 190, Issue 11, 2014, Pages 987-992

  Fakhrian, K ^a,b,c   Ordu, A D ^c   Haller, B ^c   Theisen, J ^c   Lordick, F ^c,d   Bisof V ^e   Molls, M ^c   Geinitz, H ^c,f  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e KBC Zagreb   (Croatia)

^f Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

Author keywords

Esophageal cancer; Resection; Response; Survival; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OXALIPLATIN; PLATINUM COMPLEX; RADIOSENSITIZING AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMAN; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROCEDURES; RADIATION PNEUMONITIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; RADIATION PNEUMONITIS; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84922284414     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0661-x     Document Type: Article

References (18)

1. Van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084
2. Kranzfelder M, Schuster T, Geinitz H et al (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 98:768–783
3. Lordick F, Hölscher AH, Haustermans K et al (2013) Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 398:177–187
4. Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317
5. Fakhrian K, Gamisch N, Schuster T et al (2012) Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol 188:136–142
6. Lorenzen S, Brücher B, Zimmermann F et al (2008) Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer 99:1020–1026
7. Sobin LH, Wittekind C (eds) (2002) UICC International Union Against Cancer. Esophagus (ICD-O C15). TMN classification of malignant tumors, 6th edn. Wiley-Liss, New York
8. Becker K, Mueller JD, Schulmacher C et al (1999) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 85:1484–1489
9. Woynarowski JM, Faivre S, Herzig M et al (2000) Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58:920–927
10. Saris CP, Van de Vaart PJM, Rietbroek RC et al (1996) In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis17:2763–2769
11. Woynarowski JM, Chapman WG, Napier C et al (1998) Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54:770–777
12. Winkler J1, Zipp L, Knoblich J, Zimmermann F (2012) Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advancedrectal cancer. Treatment outcome outside clinical trials. Strahlenther Onkol 188:377–382
13. Boda-Heggemann J, Weiss C, Schneider V et al (2013) Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol 189:417–423
14. Hosein PJ, Macintyre J, Kawamura C et al (2012) A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 12:199
15. Gao YH, Zhang X, An X et al (2014) Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlenther Onkol 190:158–164
16. Conroy T, Yataghène Y, Etienne PL et al (2010) Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer 103:1349–1355
17. Conroy T, Galais MP, Raoul JL et al (2012) Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): final results of the PRODIGE 5/ACCORD 17 trial. J Clin Oncol 30(18) (ASCO Annual Meeting Abstracts. June 20 Supplement)
18. Montagnani F, Turrisi G, Marinozzi C et al (2011) Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer14:50–55